Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Cybersecurity (BUG) vs Johnson & Johnson (JNJ) Price & Performance

Global X CybersecurityTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

Global X Cybersecurity vs Johnson & Johnson — how do they compare? Global X Cybersecurity trades at $42.93, while Johnson & Johnson trades at $259.89 (market cap $630.94B). The key difference: Johnson & Johnson pays a 2.05% dividend while Global X Cybersecurity pays none. Which is the better fit depends on your goals.

BUGJNJ
Sector
Sector/ThematicHealth
52-Week High
$43.00$267.24
52-Week Low
$23.30$172.78
Market Cap
$630.94B
Volume
6,156,228
Enterprise Value
$659.21B
Dividend Yield
2.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Cybersecurity

BUG, the Global X Cybersecurity ETF, trades at $41.68, up 2.36% today and near its 52-week high, with a strong bullish technical signal from moving averages. The ETF has gained significant momentum, rising 82.25% from its 52-week low, as cybersecurity spending forecasts exceed $300 billion in 2026. Recent news highlights sector resilience against AI threats, though key financial ratios like P/E and P/S are not provided in the available data.

The outlook for BUG is positive, driven by robust cybersecurity demand and AI-related security needs, but risks include premium valuations, concentrated US SMID-cap exposure, and potential sector volatility. Analyst sentiment remains bullish with reiterated buy ratings, yet investors should note overbought short-term signals and competitive pressures in the evolving tech landscape.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $259.24, up 0.88% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $282.33. Recent earnings beat expectations in Q1 and Q2 2026, with Q3 results pending. The company maintains strong profitability, including a 67.91% gross margin and 21.48% net income margin, supported by consistent dividend payments, including a recent $1.34 per share payout.

JNJ offers stability with a 64-year dividend growth streak and robust fundamentals, but risks include rising debt-to-asset ratios (24.06% in 2025) and sector volatility. Upside potential hinges on execution of growth initiatives and healthcare market dynamics, with analysts favoring a buy rating (52.5% consensus).

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Global X Cybersecurity

BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.

Read more on BUG

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ